Additionally, Khk transcript levels in all treatment groups positively correlated with those of all NAFLD driver genes (Fig. S9A), the lipogenesis promoting transcription factors Srebf1 and Pparg, and Xdh (Fig. S9B). Here, SREBF1 is linked to metabolic dysfunction-associated steatotic liver disease.